Melanoma News and reporting on melanoma. Dec 7, 2022 FDA Approves Thermo Fisher HLA Typing Test as CDx for Immunocore Uveal Melanoma Therapy Nov 21, 2022 Iovance Announces Another Regulatory Delay in Quest for First-In-Class TIL Therapy Approval Oct 27, 2022 Keytruda Revenue Climbs 20 Percent in Q3 as Merck Continues Push Into Earlier-Stage Cancer Settings Premium Oct 25, 2022 ImaginAb Doses First Patient in Study of CD8-Targeted PET Imaging Agent in Australia Oct 12, 2022 Merck Exercises Option on Moderna Cancer Vaccine Oct 10, 2022 Iovance Biotherapeutics Doses First Patient in Modified TIL Therapy Trial Oct 7, 2022 Autoantibody Test Shows It Can Predict Toxicity, Recurrence in Melanoma Patients on Immunotherapy Premium Oct 7, 2022 Lyell Immunopharma to Begin Phase I Trial of Enhanced TIL Therapy LYL845 Oct 4, 2022 Research Clarifies Immunotherapy, Targeted Treatment Order for BRAF-Mutant Melanoma Patients Premium Sep 20, 2022 Elicio Receives $2.8M Grant for Cancer Vaccine Development Sep 19, 2022 CancerRNA Consortium Will Harness RNA Technology to Enhance Immunotherapies Sep 16, 2022 BMS Combo Immunotherapy Opdualag Approved in Europe for Biomarker-Defined Melanoma Patients Sep 11, 2022 TIL Therapy Bests Yervoy in Head-to-Head Melanoma Trial; Will It Reach Patients Without Pharma? Premium Sep 6, 2022 Ideaya Begins Phase I Trial of Darovasertib in Primary Uveal Melanoma Sep 1, 2022 SkylineDx Gains CE-IVD Mark for Melanoma Metastasis Risk Assay Aug 26, 2022 Melanoma Docs Resurrect PD-L1 Debate as CHMP, FDA Diverge on Opdualag Label Premium Jul 27, 2022 BMS Reports Q2 Growth in CAR T-Cell Therapies Despite Manufacturing Hurdles Premium Jul 22, 2022 Bristol Myers Squibb's Opdualag Gets EMA CHMP Recommendation for Biomarker-Selected Melanoma Jul 21, 2022 MD Anderson, Obsidian Therapeutics to Launch First-In-Human Trial of Engineered TILs for Melanoma Jul 21, 2022 PamGene Gains CE-IVD Registration for Immunotherapy Guidance Tests Load More Breaking News Ratio Therapeutics Raises $20M in Series A Financing Guardant Health, AnHeart Tx to Develop Blood- and Tissue-Based CDx for NSCLC Drug Ellipses Pharma Cleared by FDA to Open Phase I/II AML Trial Survey Reveals Changing Genetic Testing Patterns, Persistent Disparities in Precision Oncology Amgen's Lumakras Sales Increased 58 Percent in Q4 2022 Coeptis Therapeutics, University of Pittsburgh Studying SNAP-CAR Therapy in HER2-Positive Cancers
